0000899243-21-027295.txt : 20210702
0000899243-21-027295.hdr.sgml : 20210702
20210702175006
ACCESSION NUMBER: 0000899243-21-027295
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210615
FILED AS OF DATE: 20210702
DATE AS OF CHANGE: 20210702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JORDAN WADIH
CENTRAL INDEX KEY: 0001222090
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 211071751
MAIL ADDRESS:
STREET 1: ANTIGENICS INC.
STREET 2: 162 FIFTH AVE., SUITE 900
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-15
0
0001098972
AGENUS INC
AGEN
0001222090
JORDAN WADIH
C/O AGENUS INC.
3 FORBES ROAD
LEXINGTON
MA
02421
1
0
0
0
Stock Option
3.18
2021-06-15
4
A
0
100000
0.00
A
2030-12-17
Common Stock
100000
100000
D
Deferred Stock Units
2021-07-01
4
A
0
6870.871
A
Common Stock
6870.871
195006.2
D
Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.
Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.
Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.
$3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.
/s/ Adam Krauss, as Attorney-in-Fact for Wadih Jordan
2021-07-02